Peptidoleukotriene Antagonists
State of the Art

Andreas von Sprecher*, Andreas Beck, Marc Gerspacher, and Michael A. Bray

Abstract. Peptidoleukotrienes (LTC₄, LTD₄, and LTE₄) have been proposed as important mediators of asthma. Twenty years of research in the field of peptidoleukotriene (pLT) antagonists have generated a number of biologically active compounds from different structural classes. Several drugs have been or are currently in clinical trials. The first generation peptidoleukotriene antagonists (e.g. FPL 55712) showed disappointing results in asthmatic patients, due to insufficient potency. However, new classes of highly potent antagonists (e.g. ICI 204219) are proving successful in clinical trials in asthma patients. Thus, peptidoleukotriene antagonists may represent a new principle in asthma therapy. In this paper, the in vitro potency and clinical data of different classes of peptidoleukotriene antagonists are reviewed.

Introduction

The peptidoleukotrienes C₄, D₄, and E₄ (LTC₄, LTD₄, LTE₄) are a class of local tissue hormones, which are involved in a number of regulatory processes. These endogenous mediators are metabolites of arachidonic acid (AA), which is enzymatically liberated from membrane phospholipids (Scheme). The AA can be converted to prostaglandins, prostacyclin, and thromboxane via the cyclooxygenase pathway, which can be blocked by the so-called NSAIDs (Non-Steroidal Antiinflammatory Drugs) like diclofenac or indomethacin. Via a second pathway the AA can be transformed by the enzyme 5-lipoxygenase to the epoxide LT₄, which is the precursor both for leukotriene B₄ (LTB₄) and the peptidoleukotrienes (pLTs). LTB₄ is an important inflammatory mediator with potent chemotactic activity and may also act as a modulator of inflammatory cell function. LTB₄ is implicated in various inflammatory diseases including psoriasis, inflammatory bowel disease, and rheumatoid arthritis.

In contrast, local production of pLTs is likely to be a major factor in the pathogenesis of asthma and related conditions. Constriction of bronchial smooth muscle and excessive production of bronchial mucus are characteristic symptoms evoked by pLTs, resulting in a decrease of lung volume associated with an asthma attack [1]. Consequently potent and selective pLT antagonists should be useful therapeutic agents for the treatment of this widespread disease.

After 1980, when the structures of the pLTs, previously collectively known as SRS-A (Slow-Reacting Substance of Anaphylaxis), became available, the pharmaceutical industry initiated ambitious research programs aimed at the development of pLT antagonists [2]. This review will exclusively discuss pLT antagonists which are or were in clinical trials, as well as some new and promising structures, likely to undergo clinical evaluation. A tabular format has been chosen, which allows for quick access to the relevant in vitro data and the status of clinical development for different structural classes of pLT antagonists.

Hydroxyacetophenones: Analogs of FPL 55712 (Table 1)

The first pLT antagonist, FPL 55712, was described in 1973 [3], six years before the structures of the pLTs were elucidated. For several years, FPL 55712 was practically the only lead in the search for pLT antagonists. A huge number of analogs, which share the hydroxycetophenone residue linked by a carbon chain to an acidic group, were prepared. A small number of these were evaluated in clinical trials. Although some beneficial effects in humans could be shown (e.g. LY 171883), these first generation pLT antagonists in general proved to be not potent enough to be of clinical value. Today, they are no longer regarded as lead structures, and most companies have stopped research on this class of pLT antagonists.

pLT Analogs (Table 2)

Ever since the structures of the pLTs were defined by Samuelsson and Corey [4], a new area of pLT antagonist research evolved using the natural mediators as a starting point for chemical modification. Although this was a highly sophisticated enterprise, due to the chemical liability and the complicated nature of the lead structures, four antagonists of this type (SK&F 104353, SK&F 106203, LY 170680, CGP 45715A) have been identified for testing in humans. Interestingly, SK&F 104353 and LY 170680 retain the same relative and absolute configuration of the chiral OH and thioether centers of LTD₄, whereas, in CGP 45715A the diastereoisomeric configuration is required for potent pLT antagonism. The SK&F compounds as well as LY 170680 also retain the acidic function equivalent to the carboxylic group in the eicosanoid backbone of LTD₄, whereas, in CGP 45715A the diastereoisomeric configuration is required for potent pLT antagonism. The SK&F compounds as well as LY 170680 also retain the acidic function equivalent to the carboxylic group in the eicosanoid backbone of LTD₄, whereas, in CGP 45715A the diastereoisomeric configuration is required for potent pLT antagonism. The SK&F compounds as well as LY 170680 also retain the acidic function equivalent to the carboxylic group in the eicosanoid backbone of LTD₄, whereas, in CGP 45715A the diastereoisomeric configuration is required for potent pLT antagonism. The SK&F compounds as well as LY 170680 also retain the acidic function equivalent to the carboxylic group in the eicosanoid backbone of LTD₄, whereas, in CGP 45715A the diastereoisomeric configuration is required for potent pLT antagonism. The SK&F compounds as well as LY 170680 also retain the acidic function equivalent to the carboxylic group in the eicosanoid backbone of LTD₄, whereas, in CGP 45715A the diastereoisomeric configuration is required for potent pLT antagonism. The SK&F compounds as well as LY 170680 also retain the acidic function equivalent to the carboxylic group in the eicosanoid backbone of LTD₄, whereas, in CGP 45715A the diastereoisomeric configuration is required for potent pLT antagonism. The SK&F compounds as well as LY 170680 also retain the acidic function equivalent to the carboxylic group in the eicosanoid backbone of LTD₄, whereas, in CGP 45715A the diastereoisomeric configuration is required for potent pLT antagonism. The SK&F compounds as well as LY 170680 also retain the acidic function equivalent to the carboxylic group in the eicosanoid backbone of LTD₄, whereas, in CGP 45715A the diastereoisomeric configuration is required for potent pLT antagonism. The SK&F compounds as well as LY 170680 also retain the acidic function equivalent to the carboxylic group in the eicosanoid backbone of LTD₄, whereas, in CGP 45715A the diastereoisomeric configuration is required for potent pLT antagonism. The SK&F compounds as well as LY 170680 also retain the acidic function equivalent to the carboxylic group in the eicosanoid backbone of LTD₄, whereas, in CGP 45715A the diastereoisomeric configuration is required for potent pLT antagonism. The SK&F compounds as well as LY 170680 also retain the acidic function equivalent to the carboxylic group in the eicosanoid backbone of LTD₄, whereas, in CGP 45715A the diastereoisomeric configuration is required for potent pLT antagonism. The SK&F compounds as well as LY 170680 also retain the acidic function equivalent to the carboxylic group in the eicosanoid backbone of LTD₄, whereas, in CGP 45715A the diastereoisomeric configuration is required for potent pLT antagonism. The SK&F compounds as well as LY 170680 also retain the acidic function equivalent to the carboxylic group in the eicosanoid backbone of LTD₄, whereas, in CGP 45715A the diastereoisomeric configuration is required for potent pLT antagonism. The SK&F compounds as well as LY 170680 also retain the acidic function equivalent to the carboxylic group in the eicosanoid backbone of LTD₄, whereas, in CGP 45715A the diastereoisomeric configuration is required for potent pLT antagonism. The SK&F compounds as well as LY 170680 also retain the acidic function equivalent to the carboxylic group in the eicosanoid backbone of LTD₄, whereas, in CGP 45715A the diastereoisomeric configuration is required for potent pLT antagonism. The SK&F compounds as well as LY 170680 also retain the acidic function equivalent to the carboxylic group in the eicosanoid backbone of LTD₄, whereas, in CGP 45715A the diastereoisomeric configuration is required for potent pLT antagonism. The SK&F compounds as well as LY 170680 also retain the acidic function equivalent to the carboxylic group in the eicosanoid backbone of LTD₄, whereas, in CGP 45715A the diastereoisomeric configuration is required for potent pLT antagonism. The SK&F compounds as well as LY 170680 also retain the acidic function equivalent to the carboxylic group in the eicosanoid backbone of LTD₄, whereas, in CGP 45715A the diastereoisomeric configuration is required for potent pLT antagonism. The S...
Table 1. Hydroxyacetophenones: Analogs of FPL 55712

| Compound                  | State of Development | In vitro LT Antagonism                                                                 | Clinical Trials                                                                                     |
|---------------------------|----------------------|----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|
| **FPL 55712 (Fisons)**    | Phase II aerosol;    | Inhibition of \(^{3}H\)-LT\(_D_2\) binding to guinea pig lung membranes: \(IC_{50} = 4\ \mu M\) [5]. Inhibition of LT\(_D_2\)-induced guinea pig ileum (\(pA_2 = 7.33\)), lung strip (\(pA_2 = 7.04\)) and trachea (\(pA_2 = 6.9\)) contractions [6]. | Limited clinical studies: Effective against LT\(_C_4\)-induced bronchoconstriction in two volunteers. No effect against antigen-induced bronchoconstriction in asthmatic patients. No effect in chronic asthmatics [6]. |
| (Industry standard)       | suspended            |                                                                                       |                                                                                                     |
| **Tomelukast, LY 171883** | Phase II/III oral;  | Inhibition of \(^{3}H\)-LT\(_D_2\) binding to guinea pig lung membranes: 36\% at 10 \(\mu M\) [6]. Inhibition of LT\(_D_2\)-induced guinea pig ileum contractions: \(pK_b = 7.2\) [7]. | Long-term toxicity in female mice [8]. Effective against exogenously-administered LT\(_D_2\)-induced bronchoconstriction. Attenuation of late-phase bronchospasm in allergen challenged asthmatics. Improvement of pulmonary function in patients with chronic, mild asthma [9]. |
| (Lilly)                   | suspended            |                                                                                       |                                                                                                     |
| **LY 203647**             | Preclinical          | Antagonism of LT\(_D_2\) and LT\(_E_2\)-induced guinea pig ileum contractions: \(pK_b = 7.1\) and 7.4 [10]. | Selected for clinical evaluation in cardiovascular disorders thought to be associated with excessive pLT production. |
| (Lilly)                   |                      |                                                                                       |                                                                                                     |
| **L-648051**              | Phase II aerosol;    | Inhibition of \(^{3}H\)-LT\(_D_2\) binding to guinea pig lung membranes: \(K_i = 6.2\ \mu M\) and antagonism of LT\(_D_2\)-induced guinea pig ileum contractions: \(pA_2 = 7.7\) [11]. | Effective against exogenously-administered LT\(_D_2\)-induced bronchoconstriction. No protection against early and late asthmatic response or the deterioration in bronchial hyperresponsiveness after allergen challenge in asthmatic patients [12]. |
| (Merck Frosst)            | suspended            |                                                                                       |                                                                                                     |
| **L-649923**              | Phase II oral;       | Inhibition of \(^{3}H\)-LT\(_D_2\) binding to guinea pig lung membranes: \(K_i = 0.4\ \mu M\) and antagonism of LT\(_D_2\)-induced guinea pig ileum contractions: \(pA_2 = 8.1\) [11]. | Effective against exogenously-administered LT\(_D_2\)-induced bronchoconstriction. Minor protection against early bronchospasm and no protection against late bronchospasm in patients with mild asthma after antigen challenge [13]. |
| (Merck Frosst)            | suspended            |                                                                                       |                                                                                                     |
| **Ablukast, Ro 23-3544**  | Phase I aerosol;     | Inhibition of \(^{3}H\)-LT\(_D_2\) binding to guinea pig lung membranes: \(IC_{50} = 4\ \mu M\) and antagonism of LT\(_D_2\)-induced guinea pig trachea contractions: \(pA_2 = 6.6\) [5]. | Induction of early and late bronchospasm in mildly asthmatic patients [14]. |
| (F. Hoffmann-La Roche AG) | suspended            |                                                                                       |                                                                                                     |
| **CGP 35949**             | Phase I aerosol;     | Inhibition of \(^{3}H\)-LT\(_D_2\) binding to guinea pig lung membranes: \(IC_{50} = 1\ \mu M\) and antagonism of LT\(_D_2\)-induced guinea pig ileum contractions: \(pA_2 = 8.2\) [15]. | Irritant formulation. |
| (Ciba-Geigy AG)           | suspended            |                                                                                       |                                                                                                     |
Table 1 (cont.)

| Compound                  | State of Development | In vitro LT Antagonism                                           | Clinical Trials                                                                 |
|---------------------------|----------------------|------------------------------------------------------------------|---------------------------------------------------------------------------------|
|                           |                      | Antagonism of LTD₂-ind | Moderate improvements against allergen-induced bronchoconstriction and aspirin-induced asthma in asthmatic patients [17]. |
|                           |                      |uced guinea pig ileum (IC₀₂ = 0.11 µM) and trachea (IC₀₂ = 0.16 µM) contractions [16]. |                                                                                  |

YM-16638 (Yamanouchi)

Phase II

Inhibition of [³H]-LTD₄ binding to guinea pig lung membranes: Kᵢ = 5.05 µM. Inhibition of LTD₂-induced guinea pig ileum contractions: IC₅₀ = 11 nM. (IC₅₀ values determined at Ciba-Geigy) [18].

AS-35 (Tokyo Tanabe)

Table 2. Peptidoleukotriene Analogs

| Compound                  | State of Development | In vitro LT Antagonism                                           | Clinical Trials                                                                 |
|---------------------------|----------------------|------------------------------------------------------------------|---------------------------------------------------------------------------------|
|                           |                      | Inhibition of [³H]-LTD₄ binding to guinea pig lung membranes: Kᵢ = 5 nM and antagonism of LTD₂-induced guinea pig trachea contractions: pA₂ = 8.6 [20]. | Effective against exogenously-administered LTD₂-induced, allergen and exercise-induced bronchoconstriction in asthmatics (including late-phase response) [21]. Effective against aspirin-induced asthma [22]. |
| SK&F 104353 (SmithKline Beecham) | Phase II/III, aerosol; on hold Clinical trials halted due to an irritant excipient [19]. |                                                                                  |                                                                                  |
|                           |                      | Inhibition of [³H]-LTD₄ binding to guinea pig lung membranes: Kᵢ = 19.4 nM and antagonism of LTD₂-induced guinea pig trachea contractions: pA₂ = 7.6 [23]. | Effective against LTD₂-induced bronchoconstriction in healthy volunteers [24]. |
| SK&F S-106203 (SmithKline Beecham) | Phase II, oral |                                                                                  |                                                                                  |
|                           |                      | Inhibition of [³H]-LTD₄ binding to guinea pig lung membranes: Kᵢ = 1.28 nM and antagonism of LTD₂-induced guinea pig trachea contractions: pKᵢ = 8.3 [25]. | Clinical candidate.                                                             |
| SK&F 107310 (SmithKline Beecham) | Preclinical         |                                                                                  |                                                                                  |
|                           |                      | Antagonism of LTD₂-induced guinea pig trachea (pA₂ = 8.1) and ileum (pA₂ = 8.7) contractions [26]. | Effective against LTD₂-induced bronchoconstriction in healthy volunteers [26]. |
| Sulukast, LY 170680 (Lilly) | Phase II, aerosol  |                                                                                  |                                                                                  |
|                           |                      | Inhibition of [³H]-LTD₄ binding to guinea pig lung membranes: Kᵢ = 2.2 nM and antagonism of LTD₂-induced guinea pig ileum contractions: pA₂ = 10.1 [27]. | Effective against LTD₂-induced bronchoconstriction in healthy volunteers. |
| CGP45715A (Ciba-Geigy AG) | Phase II, aerosol  |                                                                                  |                                                                                  |
Table 3. Quinolines

| Compound | State of Development | \( \text{In vitro LT Antagonism} \) | Clinical Trials |
|----------|----------------------|---------------------------------|-----------------|
| Ritolukast, Wy-48252 (Wyeth-Ayerst) | Phase I, oral; suspended | Inhibition of \(^{[3]}\text{H}\)-LT-D binding to guinea pig lung membranes: \( K_i = 35 \text{ nM} \) and antagonism of LT-D induced guinea pig trachea contractions: \( pA_2 = 7.62 \) [28]. | No clinical data available. Development discontinued following toxicity problems in monkeys [29]. |
| Wy-50295 (Wyeth-Ayerst) | Phase I | 5-Lipoxygenase inhibitor/LT antagonist. \( \text{In vitro} \) inhibition of LT biosynthesis: \( IC_{50} = 0.055 \mu \text{M to} 1.79 \mu \text{M (various cells).} \) Inhibition of \(^{[3]}\text{H}\)-LT-D binding to guinea pig lung membranes: \( K_i = 2.8 \mu \text{M} \) and antagonism of LT-D induced guinea pig trachea contractions: \( pA_2 = 6.06 \) [30]. | No clinical data available. |
| REV-5901 (Revlon) | Phase I, oral; suspended | 5-Lipoxygenase inhibitor/LT antagonist. Inhibition of 5-lipoxygenase in rat neutrophils: \( IC_{50} = 0.12 \mu \text{M. Antagonism of LTC}_{4}\)-induced guinea pig lung parenchymal strip contractions: \( IC_{50} = 3.6 \mu \text{M} \) [31]. | No effect against LT-D-induced bronchoconstriction in healthy volunteers [32]. |
| SR 2640 (Leo) | Phase II, oral; suspended | Inhibition of \(^{[3]}\text{H}\)-LT-D binding to guinea pig lung membranes: \( IC_{50} = 23 \text{ nM} \) and antagonism of LT-D induced guinea pig trachea contractions: \( pA_2 = 8.7 \) [33]. | Small effect against LT-D-induced bronchoconstriction in asthmatic humans [34]. |
| Verlukast, MK-679 | Phase II/III, intravenous, oral & aerosol; suspended | Inhibition of \(^{[3]}\text{H}\)-LT-D binding to guinea pig lung membranes: \( IC_{50} = 3.1 \text{ nM} \) and antagonism of LT-D induced guinea pig trachea contractions: \( pA_6 = 8.8 \) [35]. | MK 571: Effective against exogenously-administered LT-D-induced bronchoconstriction. Inhibition of early and late asthmatic responses after antigen challenge in asthmatic patients. Attenuation of exercise-induced bronchoconstriction in asthmatics. Beneficial effects on exercise-induced bronchoconstriction in patients with moderately severe asthmatic subjects [36]. Suspension of development due to tolerability problems [37]. |
| RG 12525 (Rhone-Poulenc Rorer) | Phase II, oral | Inhibition of \(^{[3]}\text{H}\)-LT-D binding to guinea pig lung membranes: \( K_i = 3 \text{ nM} \) and antagonism of LTC\(_4\)-LT-D or LTE\(_{4}\)-induced guinea pig parenchymal strip contractions: \( K_i = 3 \text{ nM} \) [38]. | Modest activity against LT-D-induced bronchoconstriction in asthmatics [39]. Attenuation of antigen-induced bronchoconstriction in patients with allergic asthma [40]a and improvement of lung function in asthmatic patients [40b]. |
| RG 12553 (Rhone-Poulenc Rorer) | Preclinical, aerosol | Inhibition of \(^{[3]}\text{H}\)-LT-D binding to guinea pig lung membranes: \( K_i = 0.1 \text{ nM} \) and antagonism of LT-D induced guinea pig parenchymal strip contractions: \( IC_{50} = 0.5 \text{ nM} \) [41]. | |
| LY 287192 (Lilly) | Preclinical | Antagonism of LT-D induced guinea pig ileum contractions: \( pK_i = 9.1 \) [42]. | |
search, produced analogs of FPL 55712. Now, around ten years later pLT antagonists of the quinoline type, first synthesized by Wyeth-Ayerst, are the preferred target of the pharmaceutical industry. In general, simple synthesis, chemical stability, high \textit{in vitro} potency and, compared to FPL 55712 analogs, good oral activity are the reasons for the attractiveness of quinolines. In addition, many compounds have the additional property of being LT biosynthesis inhibitors.

The 2-substituted quinoline residue plays an equally important role for these pLT antagonists as did the hydroxyacetophenone residue in analogs of FPL 55712. In each structural class, these groups are absolutely essential to achieve potent pLT antagonist activity. Quinoline pLT antagonists share the following structural principles: the quinoline nucleus is attached via a two-atom spacer to an aromatic residue linked to an acidic function.

Table 4. \textit{Thiazoles}

| Compound | State of Development | \textit{In vitro} LT Antagonism | Clinical Trials |
|----------|----------------------|-------------------------------|-----------------|
| MCI-826 (Mitsubishi) | Phase I | Inhibition of $[^{3}H]$-LTD$_4$ binding to guinea pig lung membranes: $IC_{50} = 7 \text{ nM}$ and antagonism of LTD$_4$-induced guinea pig ileum contractions: $IC_{50} = 0.56 \text{ nM}$. ($IC_{50}$ values determined at Ciba-Geigy.) [43] | No clinical data available. |
| Ro 24-5913 (F. Hoffmann-La Roche AG) | Phase I | Inhibition of $[^{3}H]$-LTD$_4$ binding to guinea pig lung membranes: $IC_{50} = 6.4 \text{ nM}$ and antagonism of LTD$_4$-induced guinea pig trachea contractions: $pA_2 = 9.6$ [44]. | No clinical data available. |

Table 5. \textit{Indazole and Indoles}

| Compound | State of Development | \textit{In vitro} LT Antagonism | Clinical Trials |
|----------|----------------------|-------------------------------|-----------------|
| ICI 198615 (ICI) | Preclinical | Inhibition of $[^{3}H]$-LTD$_4$ binding to guinea pig lung membranes: $K_i = 0.28 \text{ nM}$ and antagonism of LTE$_4$-induced guinea pig tracheal strip contractions: $pK_B = 10.26$ [45]. | Poor bioavailability following oral administration in guinea pigs, rats, and dogs. Pharmacological tool [46]. |
| ICI 204219 (ICI) | Phase III, oral & aerosol | Inhibition of $[^{3}H]$-LTD$_4$ binding to guinea pig lung membranes: $K_i = 0.34 \text{ nM}$ and antagonism of LTE$_4$-induced guinea pig tracheal strip contractions: $pK_B = 9.67$ [47]. | Effective against exogenously-administered LTD$_4$-induced bronchoconstriction. Effective against allergen- [48] or exercise- [49] induced bronchoconstriction in asthmatics. Attenuation of allergen-induced airway hyperreactivity [48b]. Improvement of lung function in asthmatic patients [50]. |
| CGP 44825 (Ciba-Geigy AG) | Preclinical, oral & aerosol | Antagonism of LTD$_4$ and LTE$_4$-induced guinea pig ileum contractions: $IC_{50} = 0.56 \text{ nM}$ and 0.59 nM respectively. Antagonism of pLT-induced guinea pig lung strip contractions: $pA_1$, LTD$_4 = 7.9$; $pA_2$, LTE$_4 = 8.7$ [51]. | |

Thiazoles (Table 4)

The thiazole pLT antagonists, discovered by \textit{Mitsubishi}, are structurally related to the quinolines, in that the thiazole residue can be regarded as a replacement of
the quinoline nucleus. With respect to oral potency, bioavailability, and duration of action in guinea pigs, Ro 24-5913 is one of the most interesting pLT antagonists known. If these findings can be translated into patients, Ro 24-5913 will be an interesting clinical candidate.

Indazoles and Indoles (Table 5)

The substituted indazole and indole derivatives ICI 198615 and ICI 204219 are among the most potent LTD4 antagonists known to date. Structural similarities between a series of FPL 55712 analogs and a series of pLT analogs led to the synthesis of this innovative class of compounds. The (cyclopentoxycarbonyl)-amino-substituted indazole-indole residue is a mimic of the hydroxyacetophenone part of FPL 55712, and the para-benzylbenzoic-acid mimics the conjugated triene system of the pLTs. Although ICI 198615 and ICI 204219 are equipotent in vitro, ICI 204219 was preferred for development due to much better oral activity in vivo. ICI 204219 is one of the most advanced pLT antagonists in the clinic. Successful phase II/III studies justify the hope that ICI 204219 will be the first marketed pLT antagonist.

ICI 198615 is a valuable pharmacological tool. The tritiated molecule has been used for investigations of pLT receptors.

Miscellaneous Structures (Table 6)

ONO-1078 is well advanced in clinical development and is reported to show beneficial effects in asthmatic patients. The structure of ONO-1078 can be derived from FPL 55712, although the hydroxyacetophenone residue is replaced by a Ph group.

Ibudilast (KC-404, Ketals®) is the only 'pLT antagonist' on the market in Japan. The compound does not bind to the LTD4 receptor and has weak functional pLT antagonist properties. The antiasthmatic activity observed in man may be attributed to a number of other biological activities of this molecule.

Conclusion

The mainstay of current asthma therapy are still bronchodilators which treat the acute asthma attack. β-Agonists and xanthines are the drugs currently used to relieve the bronchoconstriction. However, these medications probably have little or no effect on airway inflammation and the late phase bronchoconstriction seen in many asthmatics. Inflammatory processes, likely to be responsible for bronchial hyperresponsiveness, can only be treated by inhaled or oral corticosteroids. Mast cell stabilizers like disodium cromoglycate, which are said to prevent inflammatory mediator release, can be used as a prophylactic treatment only in mild to moderate asthmatics. Shortcomings of bronchodilators and side effects of corticosteroids require new approaches in the treatment of asthmatic diseases, especially the inflammatory response in the asthmatic airway. Since pLTs are mediators of bronchoconstriction and bronchial hyperresponsiveness, pLT antagonists should be useful therapeutic agents for the treatment of asthma and related conditions. Clinical results with highly potent pLT antagonists, such as SK&F 104353, Verlukast, ICI 204219, and ONO-1078, appear to confirm this hypothesis. The beneficial effects obtained in asthmatic patients include protection against allergen or exercise induced early and late phase bronchoconstriction, attenuation of antigen-provoked airway hyperreactivity and bronchodilation. Further clinical trials are needed to fully explore the potential of pLT antagonists in asthma. The pLTs have been proposed to be involved in a variety of other diseases and the availability of...
potent, selective antagonists in clinical development will allow an exploration of the role of pLTs in such diseases and, potentially, markedly expand the therapeutics profile of this class of drugs. Today, it seems certain, at least that pLT antagonists will find their place in the management of asthmatic diseases.

M. Hibi, K. Shikada, T. lwama, A. Yamamoto, M. Sakashita, S. Tanaka, Jpn. J. Pharmacol. 1989, 51, 411.

The role of pLTs in such diseases and, it seems certain, at least that pLT antagonists will find their place in the management of asthmatic diseases.

M. Hibi, K. Shikada, T. lwama, A. Yamamoto, M. Sakashita, S. Tanaka, Jpn. J. Pharmacol. 1989, 51, 411.

M. Hibi, K. Shikada, T. lwama, A. Yamamoto, M. Sakashita, S. Tanaka, Jpn. J. Pharmacol. 1989, 51, 411.